Special News: VIVUS, Inc. (NASDAQ:VVUS), Synta Pharmaceuticals Corp. (NASDAQ:SNTA), Idenix Pharmaceuticals Inc (NASDAQ:IDIX)

VIVUS, Inc. (NASDAQ:VVUS)’s shares jumped 0.62% to $4.86. The company on June 12 announced that it has filed a lawsuit in the U.S. District Court for the District of New Jersey against Actavis Laboratories FL, Inc., Actavis, Inc., and Actavis PLC, collectively referred to as Actavis.

Get the Inside Scoop On VVUS here with this Free Report

The lawsuit was filed in response to an Abbreviated New Drug Application, or ANDA, filed by Actavis. In its application, Actavis seeks to market and sell generic versions of the currently approved doses of Qsymia® (phentermine and topiramate extended-release) capsules CIV prior to the expiration of U.S. Patents 7,056,890, 7,553,818, 7,659,256, 7,674,776, 8,580,298, and 8,580,299, which are listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange Book. VIVUS filed the lawsuit on the basis that Actavis’s proposed generic products infringe each of these patents held by VIVUS.

Synta Pharmaceuticals Corp. (NASDAQ:SNTA)’s shares decreased 0.23% to $4.40. The 52 week trading range for the company is $3.70 – $7.85. The company is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing small molecule drugs to severe the medical conditions of the patients with cancer and inflammatory diseases. As of December 31, 2011, it had two drug candidates in clinical trials for treating multiple types of cancer and several drug candidates in the preclinical-stage of development.

You won’t believe what we found out about SNTA

Idenix Pharmaceuticals Inc (NASDAQ:IDIX)’s shares gained 0.84% to $24.06. The securities litigation law firm of Brower Piven, A Professional Corporation, on June 16 has commenced an investigation into possible breaches of fiduciary duty to current shareholders of Idenix Pharmaceuticals, Inc. (IDIX) and other violations of state law by the board of directors of Merck & Co., Inc. (“Merck”), in a transaction valued at approximately $3.85 billion. Under the terms of the transaction, shareholders of Idenix would receive $24.50 in cash for each share of Idenix they own.

Why Should You Buy IDIX Now? Get The Free Trend Analysis Here

Joe Dashiell was raised in the Twin Cities and is a graduate of the University of St. Thomas. During his free time, he enjoys volunteering and being with friends and family. He is an avid fan of movies and loves to write, shoot, and edit them in his spare time. He is also a musician at heart and plays piano and guitar. He began his journalism career when he was 15-years-old. He and a group of friends competed in NASA's Student Journalism Competition. After winning the National 1st Prize, they were flown out to the Johnson Space Center in Houston Texas to present their project. Shortly afterwards he realized that he wanted to be a journalist.